RedHill Biopharma (RDHL) Current Leases (2019 - 2025)

RedHill Biopharma (RDHL) has reported Current Leases for 7 consecutive years, with $900000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Current Leases rose 29900.0% year-over-year to $900000.0 in Q4 2025; TTM through Dec 2025 was $900000.0, a 29900.0% increase from a year earlier, with the FY2025 full-year figure at $900000.0, up 29900.0% from the prior year.
• Current Leases was $900000.0 for Q4 2025 at RedHill Biopharma, up from $3000.0 in the prior quarter.
• Over five years, Current Leases peaked at $7.2 million in Q1 2022 and troughed at $3000.0 in Q4 2024.
• A 5-year average of $3.3 million and a median of $2.9 million in 2021 frame the typical range for Current Leases.
• Across the five-year window, Current Leases tumbled 99.34% in 2024 and jumped 29900.0% in 2025, its largest moves.
• Over 5 years, Current Leases stood at $2.6 million in 2021, then soared by 150.31% to $6.4 million in 2022, then tumbled by 92.94% to $455000.0 in 2023, then plunged by 99.34% to $3000.0 in 2024, then jumped by 29900.0% to $900000.0 in 2025.
• The last three Current Leases figures came in at $900000.0 (Q4 2025), $3000.0 (Q4 2024), and $190000.0 (Q2 2024), per Business Quant data.